SRRK

Scholar Rock Holding Corporation NASDAQ Listed May 25, 2018

Healthcare ·Biotechnology ·US · scholarrock.com

$47.07

After hrs $47.11 +0.08%

Mkt Cap $5.4B

52w Low $27.07 81.4% of range 52w High $51.62

50d MA $46.08 200d MA $40.21

P/E (TTM) -14.1x

EV/EBITDA -13.1x

P/B 21.7x

Debt/Equity 0.4x

ROE -154.0%

P/FCF -16.8x

RSI (14) —

ATR (14) —

Beta 0.69

50d MA $46.08

200d MA $40.21

Avg Volume 1.5M

About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 3, 2026	AMC	-0.88	-0.88	+0.3%	44.31	+3.3%	+7.0%	+4.2%	+2.2%	-0.2%	+1.1%	—
Nov 14, 2025	AMC	-0.84	-0.90	-7.8%	37.41	-1.6%	-2.5%	+6.4%	+6.1%	+1.6%	+7.5%	—
Aug 6, 2025	AMC	-0.66	-0.98	-48.5%	34.62	-0.0%	-9.3%	-7.7%	-9.1%	-7.0%	-7.6%	—
May 14, 2025	AMC	-0.63	-0.67	-6.3%	30.54	+0.1%	+0.9%	+0.0%	-1.2%	+3.3%	+0.6%	—
Feb 27, 2025	AMC	-0.60	-0.60	+0.0%	35.96	-0.7%	+8.0%	+0.8%	+3.1%	+0.5%	+0.5%	—
Nov 12, 2024	AMC	-0.58	-0.66	-13.8%	26.66	+2.7%	+2.7%	+3.2%	-0.6%	-1.1%	+4.5%	—
Aug 8, 2024	AMC	-0.61	-0.60	+1.6%	8.17	+1.6%	+3.4%	+16.0%	+18.8%	+12.7%	+14.8%	—
May 7, 2024	AMC	-0.51	-0.59	-15.7%	14.69	-4.0%	-1.3%	-1.0%	-9.1%	-7.1%	-4.6%	—
Mar 19, 2024	AMC	-0.49	-0.50	-2.0%	15.15	-1.1%	+8.6%	+13.5%	+8.2%	+5.7%	-1.0%	—
Nov 7, 2023	AMC	-0.53	-0.53	+0.0%	12.35	+0.4%	-3.2%	-17.4%	-18.7%	-20.0%	-10.5%	—
Aug 9, 2023	AMC	-0.56	-0.47	+16.1%	6.09	+3.1%	+11.3%	+15.8%	+16.9%	+13.3%	+9.0%	—
May 9, 2023	AMC	-0.57	-0.49	+14.0%	8.51	+1.1%	-1.5%	-5.5%	-5.8%	-2.1%	-2.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 21	Canaccord Genuity	Initiates	Buy	$62	$47.80	$48.00	+0.4%	+0.6%	-1.0%	-0.7%	-2.8%	-3.2%
Apr 1	Wedbush	Maintains	Outperform → Outperform	—	$49.16	$49.88	+1.5%	+0.4%	+1.7%	-0.7%	+1.5%	+1.7%
Mar 16	JP Morgan	Maintains	Overweight → Overweight	—	$40.01	$40.27	+0.6%	+0.6%	+1.7%	-0.5%	+13.7%	+11.6%
Mar 4	Truist	Maintains	Buy → Buy	—	$44.31	$45.79	+3.3%	+7.0%	+4.2%	+2.2%	-0.2%	+1.1%
Mar 4	Piper Sandler	Maintains	Overweight → Overweight	—	$44.31	$45.79	+3.3%	+7.0%	+4.2%	+2.2%	-0.2%	+1.1%
Mar 4	Barclays	Maintains	Overweight → Overweight	—	$44.31	$45.79	+3.3%	+7.0%	+4.2%	+2.2%	-0.2%	+1.1%
Mar 4	Citigroup	Maintains	Buy → Buy	—	$44.31	$45.79	+3.3%	+7.0%	+4.2%	+2.2%	-0.2%	+1.1%
Mar 4	BMO Capital	Maintains	Outperform → Outperform	—	$44.31	$45.79	+3.3%	+7.0%	+4.2%	+2.2%	-0.2%	+1.1%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.48	$45.25	+4.1%	+1.9%	+9.1%	+6.1%	+4.2%	+1.7%
Jan 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$44.29	$44.29	+0.0%	+1.4%	-0.7%	-2.6%	+1.4%	+0.1%
Dec 17	Barclays	Maintains	Overweight → Overweight	—	$44.32	$45.32	+2.3%	-0.7%	-3.1%	-0.9%	+2.0%	+3.5%
Nov 18	JP Morgan	Maintains	Overweight → Overweight	—	$36.47	$36.92	+1.2%	+9.2%	+8.8%	+4.3%	+10.3%	+14.6%
Nov 17	Barclays	Maintains	Overweight → Overweight	—	$37.41	$36.81	-1.6%	-2.5%	+6.4%	+6.1%	+1.6%	+7.5%
Oct 20	Truist	Maintains	Buy → Buy	—	$27.94	$28.17	+0.8%	-0.1%	+0.8%	+2.1%	+2.6%	+6.2%
Sep 24	Barclays	Maintains	Overweight → Overweight	—	$33.75	$33.39	-1.1%	-0.1%	+2.2%	+14.8%	+13.7%	+10.3%
Sep 24	Piper Sandler	Maintains	Overweight → Overweight	—	$33.75	$33.39	-1.1%	-0.1%	+2.2%	+14.8%	+13.7%	+10.3%
Sep 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.58	$29.90	-8.2%	+3.6%	+3.5%	+5.9%	+18.9%	+17.7%
Aug 7	BMO Capital	Maintains	Outperform → Outperform	—	$34.62	$34.61	-0.0%	-9.3%	-7.7%	-9.1%	-7.0%	-7.6%
Nov 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.72	$38.05	+0.9%	-1.7%	+1.1%	+5.8%	+0.6%	+4.4%
Nov 25	Truist	Maintains	Buy → Buy	—	$29.92	$40.00	+33.7%	+26.1%	+23.9%	+27.5%	+33.4%	+26.9%
Nov 25	Wedbush	Maintains	Outperform → Outperform	—	$29.92	$40.00	+33.7%	+26.1%	+23.9%	+27.5%	+33.4%	+26.9%
Nov 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$28.15	$28.50	+1.2%	-5.3%	-2.7%	-2.3%	-5.9%	-6.3%
Oct 15	Piper Sandler	Maintains	Overweight → Overweight	—	$28.52	$28.93	+1.4%	+0.1%	+1.7%	+2.6%	+7.1%	+5.0%
Oct 14	JP Morgan	Maintains	Overweight → Overweight	—	$26.51	$25.35	-4.4%	+7.6%	+7.7%	+9.4%	+10.3%	+15.2%
Oct 11	BMO Capital	Maintains	Outperform → Outperform	—	$26.14	$25.37	-2.9%	+1.4%	+9.1%	+9.2%	+10.9%	+11.9%
Oct 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.28	$33.09	-3.5%	-14.0%	-19.0%	-23.7%	-22.7%	-16.8%
Oct 7	Wedbush	Maintains	Outperform → Outperform	—	$7.42	$26.34	+255.0%	+362.0%	+297.4%	+274.3%	+252.3%	+257.3%
Oct 3	JP Morgan	Maintains	Overweight → Overweight	—	$7.35	$7.27	-1.1%	-3.8%	+1.0%	+366.4%	+301.2%	+277.8%
Aug 9	BMO Capital	Maintains	Outperform → Outperform	—	$8.17	$8.30	+1.6%	+3.4%	+16.0%	+18.8%	+12.7%	+14.8%
Jun 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.41	$8.37	-0.5%	-4.0%	-6.8%	-0.6%	-1.0%	-3.3%
Jun 13	BMO Capital	Maintains	Outperform → Outperform	—	$9.39	$9.88	+5.2%	+0.4%	+0.6%	-6.5%	-9.6%	-11.6%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.48	$9.58	+1.1%	+3.4%	+3.7%	-0.5%	+0.3%	+1.6%
May 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.71	$11.80	+0.8%	-7.9%	-8.9%	-11.8%	-21.3%	-19.8%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.69	$14.10	-4.0%	-1.3%	-1.0%	-9.1%	-7.1%	-4.6%
Apr 3	Truist	Maintains	Buy → Buy	—	$15.72	$15.65	-0.4%	-3.1%	-8.4%	-8.5%	-7.8%	-5.7%
Mar 26	Piper Sandler	Maintains	Overweight → Overweight	—	$16.01	$16.23	+1.4%	-6.3%	-3.5%	+10.9%	+4.9%	-1.8%
Mar 25	Truist	Maintains	Buy → Buy	—	$16.39	$16.18	-1.3%	-2.3%	-8.5%	-5.7%	+8.4%	+2.4%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.20	$12.81	-3.0%	+14.8%	+24.6%	+30.3%	+24.2%	+21.3%
Oct 25	Jefferies	Upgrade	Hold → Buy	—	$7.66	$8.46	+10.4%	+17.8%	+38.5%	+35.0%	+50.5%	+53.5%
Oct 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.85	$7.73	+12.8%	+17.7%	+14.5%	+20.6%	+27.0%	+9.8%
Aug 10	Wedbush	Maintains	Outperform → Outperform	—	$6.09	$6.28	+3.1%	+11.3%	+15.8%	+16.9%	+13.3%	+9.0%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.09	$6.28	+3.1%	+11.3%	+15.8%	+16.9%	+13.3%	+9.0%
Jul 13	Wedbush	Maintains	Outperform → Outperform	—	$7.00	$6.99	-0.1%	-0.4%	+0.3%	+3.3%	+3.0%	+1.6%
Jul 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.00	$6.99	-0.1%	-0.4%	+0.3%	+3.3%	+3.0%	+1.6%
Mar 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.92	$9.99	+0.7%	+0.6%	-0.6%	-8.0%	-4.0%	+3.7%
Nov 18	JP Morgan	Maintains	Overweight → Overweight	—	$9.06	$9.08	+0.2%	-6.0%	-12.4%	-12.1%	-13.1%	-12.5%
Nov 15	BMO Capital	Maintains	Outperform → Outperform	—	$8.59	$8.90	+3.6%	+9.8%	+5.4%	+5.5%	-0.8%	-7.6%
Aug 9	BMO Capital	Maintains	Outperform → Outperform	—	$8.52	$8.57	+0.6%	+6.7%	+18.7%	+20.0%	+32.6%	+32.5%
Jul 12	Truist	Maintains	Buy → Buy	—	$8.09	$8.41	+4.0%	-1.1%	+4.2%	-0.7%	-1.4%	-3.6%
Jun 23	Piper Sandler	Maintains	Overweight → Overweight	—	$5.46	$5.35	-2.0%	+14.1%	+9.2%	+34.4%	+5.5%	-0.7%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

The vague forward-looking statement language provides minimal concrete information about SRRK's actual business developments, leaving investors unable to assess material changes or upcoming catalysts affecting stock valuation.

Mar 31

8-K · 7.01 ! Medium

Scholar Rock Holding Corporation -- 8-K 7.01: Regulation FD Disclosure

Scholar Rock Holding Corporation will host a March 3, 2026 earnings call to discuss full-year 2025 results and provide a business update via presentation slides.

Mar 3

8-K · 7.01 ! Medium

Scholar Rock Holding Corporation -- 8-K 7.01: Regulation FD Disclosure

Scholar Rock (SRRK) will present 2025 financial results and business updates via conference call on March 3, 2026 at 8:15 am ET, with slides available for investors.

Mar 3

Data updated apr 27, 2026 2:51am · Source: massive.com